Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...
The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, ...
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
The young man died of acute liver injury, a known side effect, Sarepta said in a statement. But the company said the ...
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
Sarepta Therapeutics said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for a rare muscular dystrophy.
One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech ...
The patient underwent treatment in December with Sarepta's therapy, called Elevidys, the company told Reuters in an emailed statement. Elevidys is the only FDA-approved gene therapy for Duchenne ...